Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume After Analyst Upgrade

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw unusually-strong trading volume on Wednesday after Raymond James Financial upgraded the stock from an outperform rating to a strong-buy rating. Raymond James Financial now has a $123.00 price target on the stock, up from their previous price target of $63.00. Approximately 1,237,645 shares changed hands during mid-day trading, an increase of 33% from the previous session’s volume of 929,430 shares.The stock last traded at $86.0860 and had previously closed at $86.92.

Several other equities analysts have also weighed in on the stock. Wedbush raised their price objective on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a research report on Tuesday. Robert W. Baird boosted their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday. HC Wainwright increased their target price on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research note on Monday. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday. Finally, Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $115.33.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “go” decision for the CAPTIVATE CIDP trial based on an interim responder analysis — management signaled an early advancement decision that sets a major clinical catalyst (topline CIDP data expected later). This materially boosts the company’s clinical outlook and is a primary driver of recent upside. Go Decision Article
• Positive Sentiment: Multiple analyst upgrades and price‑target increases (examples: Truist to $110, Raymond James to $123, Robert W. Baird to $132, HC Wainwright bullish, Guggenheim reiterates buy) are increasing buy‑side conviction and likely supporting higher stock bids. Truist Price Target HC Wainwright Note
• Neutral Sentiment: Dianthus priced an upsized underwritten offering to raise roughly $625M (7,313,582 shares at $81.00 plus pre‑funded warrants), providing substantial cash to fund development programs — this reduces financing risk but increases share count and potential supply. Closing subject to customary conditions; underwriters have a 30‑day option for more shares. Offering Press Release
• Negative Sentiment: News of the stock offering and earlier coverage of a proposed $400M deal prompted near‑term selling and headlines about share weakness — issuance at the market can create downward pressure despite favorable pricing, which likely explains intraday pullbacks after the clinical headlines. Offering Reaction
• Negative Sentiment: Company disclosed a new AI integration–related risk (cyber, privacy, reputational exposure). This is an incremental risk factor that could concern some institutional investors focused on governance and operational risk. AI Risk Disclosure

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the second quarter valued at approximately $27,000. Parkside Financial Bank & Trust boosted its stake in Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics during the 4th quarter worth approximately $40,000. Russell Investments Group Ltd. purchased a new position in Dianthus Therapeutics during the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC raised its stake in Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Performance

The firm’s 50 day simple moving average is $50.98 and its 200-day simple moving average is $41.92. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -20.94 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. As a group, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.